• Cannara Biotech refinanced its bank debt through an amended and restated syndicated credit facility with BMO, joined by TD.
• Total committed borrowing capacity lifted to $80 million from about $50 million previously accessible.
• Facility split into a $40 million term loan for refinancing and Valleyfield capital spending, and a $40 million revolving credit facility.
• Committed revolving capacity increased to $40 million from $10 million, boosting liquidity for working capital and general corporate needs.
• Maturity extended to Dec. 31, 2029 from Dec. 31, 2027, pushing out the company’s debt wall by two years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cannara Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609100800PRIMZONEFULLFEED9824354) on September 10, 2026, and is solely responsible for the information contained therein.